Effect of FGFR alteration on prognosis in 1963 urothelial carcinoma patients with immune checkpoint inhibitors: Implying combination of FGFR inhibitor and immunotherapy for FGFR-altered urothelial carcinoma

Immune checkpoint inhibitors (ICIs) are essential for urothelial carcinoma (UC) treatment.Fibroblast growth factor receptor (FGFR) alterations, as common oncogenic drivers in UC, have been Sound Bar Mount reported to drive T cell depletion of UC immune microenvironment via up-regulating FGFR signaling, which indicated FGFR alterations potentially r

read more